0 0 0 0 0 0.00144827586206902 -0.00455172413793101 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences (NASDAQ:GILD) Chief Financial Officer Andrew Dickinson told investors at the Barclays conference that the company is entering what he described as “the beginning of a long cycle,” supported by recent launches, a broadening pipeline, and continued operating discipline. Dickinson said Gilead had an “extraordinary 2025” across its base business, clinical results and commercial execution, highlighting two major product launches: YEZTUGO, its once-every-six-month subcutaneous HIV prevention medicine, and LIVDELZI, which is in its first full year on the market for primary biliary cholangitis (PBC). He emphasized “very strong operating expense control,” “significant growth in EPS,” and what he called the strongest pipeline in the company's history. Arcellx acquisition: “best-in-class” BCMA cell therapy ? Amazon Is Rising While the Market Falls—Here's Why These 3 Cash Flow Machines Provide Stability in Uncertain Markets Dickinson discussed Gilead's decision to acqui [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences (NASDAQ:GILD) Chief Financial Officer Andrew Dickinson told investors at the Barclays conference that the company is entering what he described as “the beginning of a long cycle,” supported by recent launches, a broadening pipeline, and continued operating discipline. Dickinson said Gilead had an “extraordinary 2025” across its base business, clinical results and commercial execution, highlighting two major product launches: YEZTUGO, its once-every-six-month subcutaneous HIV prevention medicine, and LIVDELZI, which is in its first full year on the market for primary biliary cholangitis (PBC). He emphasized “very strong operating expense control,” “significant growth in EPS,” and what he called the strongest pipeline in the company's history. Arcellx acquisition: “best-in-class” BCMA cell therapy ? Amazon Is Rising While the Market Falls—Here's Why These 3 Cash Flow Machines Provide Stability in Uncertain Markets Dickinson discussed Gilead's decision to acqui [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS